
B2i Digital Campaign to Center on Nu-3, the Upcoming Phase 2a Trial, and the Bisphosphocin® Class Behind It

Lakewood-Amedex is advancing Nu-3, a novel topical antimicrobial candidate for infected diabetic foot ulcers, supported by an extensive patent portfolio and planned Phase 2a study.
Clinical-Stage Biotechnology Company Is Preparing a Phase 2a Trial of Nu-3, a Topical Bisphosphocin® Gel, in Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT)
Working with B2i Digital gives us the opportunity to explain that science, and the milestones ahead of it, to a much broader group of investors than a company at our stage would normally reach.”— Kelvin Cooper, Ph.D., CEO of Lakewood-Amedex Biotherapeutics Inc.
NEW YORK, NY, UNITED STATES, August 25, 2026 /EINPresswire.com/ -- B2i Digital, Inc. today welcomed Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) as its newest Featured Company. The Sarasota, Florida clinical-stage biotechnology company develops the Bisphosphocin® class, a novel group of fast-acting, broad-spectrum